La lecture en ligne est gratuite
Le téléchargement nécessite un accès à la bibliothèque YouScribe
Tout savoir sur nos offres
Télécharger Lire

Sigma-Tau Group Begins Roll-Out of New Anti-Malaria Drug, Eurartesim® (Dihydroartemisinin-Piperaquine)

2 pages
Sigma-Tau Group Begins Roll-Out of New Anti- Malaria Drug, Eurartesim® (Dihydroartemisinin- Piperaquine) PR Newswire ROME, July 5, 2012 ROME, July 5, 2012 /PRNewswire/ -- Eurartesim® (dihydroartemisinin piperaquine: DHA-PQP), the first artemisinin combination therapy (ACT) approved by the European Medicines Agency (EMA) for the
Voir plus Voir moins
Sigma-Tau Group Begins Roll-Out of New Anti-
Malaria Drug, Eurartesim® (Dihydroartemisinin-
Piperaquine)
PR Newswire
ROME, July 5, 2012
ROME
,
July 5, 2012
/PRNewswire/ --
Eurartesim® (dihydroartemisinin piperaquine: DHA-PQP), the first artemisinin
combination therapy (ACT) approved by the European Medicines Agency (EMA)
for the treatment of uncomplicated malaria, is being prepared for roll-out in
several countries. Eurartesim®, was developed collaboratively by Sigma Tau
Group,
Italy
, and the not-for-profit research foundation Medicines for Malaria
Venture (MMV).
The EMA-approved Eurartesim® is now ready for delivery to
Cambodia
, the
first malaria endemic country to place an order for this newly approved
treatment.
Cambodia
prioritized the use of DHA-PQP as a first line drug and
was awaiting EMA approval to allow procurement of this product using
international donor funds.
The World Health Organization's standard treatment guidelines recommend
DHA-PQP as a highly effective ACT in curing uncomplicated malaria. In early
June, Sigma Tau submitted Eurartesim® for prequalification by the World
Health Organization, a process highly regarded by donors, and malaria-
endemic countries, as an important measure of quality and efficacy of new
drugs. In addition, Sigma Tau is about to submit the drug for registration in key
African countries, e.g.,
Burkina Faso
,
Mozambique
,
Tanzania
,
Ghana
and
others.
Professor Trevor Jones of the Sigma-Tau Group Board of Directors
commented, "
Eurartesim
represents a major innovation in the fight against the
malaria. We are proud to announce that we continue to work towards achieving
registration and distribution of the drug in malaria-endemic countries where
thousands of people die each year from this disease. We are also ensuring its
availability in
Europe
."
Although priority areas remain malaria-endemic countries, with marketing
authorization from the EMA, Sigma Tau is planning to roll-out Eurartesim®
across
Europe
, for use both by travellers to malaria-endemic countries and for
imported cases of malaria in the case of returning travellers. Eurartesim® is
already available in pharmacies
in
France
, UK,
Germany
,
Belgium
and
Portugal
, where the number of
cases have been the highest in
Europe
.
Eurartesim® was selected as the Medicines for Malaria Venture Project of the
Year 2011, in recognition of its important contribution to the universe of
quality-assured efficacious medicines for curing malaria.
Sigma-Tau Group
Sigma-Tau is a leading, all Italian capital, International pharmaceutical Group,
founded in 1957, that invests in the research, development and marketing of
innovative and effective treatments to improve human well-being and quality of
life.
Sigma-Tau Group has headquarters in Pomezia (Rome, Italy). With about 2400
employees and an extensive network of subsidiaries and licensees worldwide,
the Group's 2011 global turnover was equal to € 663 million.
Website - http://www.sigma-tau.it
For additional information:
Sigma-Tau Communications and Information Manager
Bruno Chiavazzo
Tel. +39-(0)6-91394181
e-mail: bruno.chiavazzo@sigma-tau
Press Officer:
Noesis Comunicazione
Giovanna Vetere
Tel. +39-(0)2-83105122
Cell. +39-348-7022510
e-mail:giovanna.vetere@noesis.net
Un pour Un
Permettre à tous d'accéder à la lecture
Pour chaque accès à la bibliothèque, YouScribe donne un accès à une personne dans le besoin